South Korea Begins Push for New Antibiotic Development Amid Resistance Crisis

South Korea, once reliant on scarce antibiotics during the Korean War, now faces a significant challenge with its high rate of antibiotic consumption. The nation ranks among the top users of antibiotics within the OECD, a trend that directly correlates with a rise in bacteria resistant to these drugs. This escalating resistance poses a serious threat to modern medicine, undermining the safety of procedures like post-surgical infection prevention and cancer chemotherapy, which depend heavily on effective antibiotics.

The World Health Organization (WHO) has warned of dire consequences, projecting that 10 million people could die annually from antibiotic resistance by 2050 if current trends persist. To combat this global health crisis, two primary strategies exist: reducing antibiotic use and ensuring it is reserved for essential cases, and developing novel antibiotics to overcome existing resistance.

South Korea has been actively pursuing the first strategy since 2016, establishing and refining national action plans to manage antibiotic use. However, the country has been notably slow in addressing the second strategy – the development of new antibiotics. This is largely due to economic factors, as the low price of antibiotics offers little incentive for private pharmaceutical companies to invest in research and development.

Recognizing this gap, the government has recently taken a crucial first step. The Korea Disease Control and Prevention Agency's National Institute of Health convened a kickoff meeting on May 20th to foster the development of new antibiotics. The institute announced its intention to create a national technical support system to connect scattered research infrastructure and expertise across the country. While this initiative may be considered a late start, it represents a vital move towards safeguarding public health. With projections indicating that antibiotic resistance could cause 32,400 deaths in South Korea by 2030 under current trends, the development of new drugs, alongside continued efforts to manage usage, is essential to significantly lower this mortality rate.